Mark Holdbrook
YOU?
Author Swipe
View article: Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study
Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study Open
Purpose: The aim of this study was to evaluate the long-term outcomes of lotilaner ophthalmic solution, 0.25%, in the treatment of Demodex blepharitis. Methods: This observational, extension study included patients with Demodex blepharitis…
View article: The impact of Demodex blepharitis on patient symptoms and daily life
The impact of Demodex blepharitis on patient symptoms and daily life Open
SIGNIFICANCE Patients with Demodex blepharitis have a considerable symptomatic burden that negatively impacts their daily activities and well-being. Despite chronic manifestations of and problems associated with blepharitis that resulted i…
View article: Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis
Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis Open
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
View article: Psychosocial Impact of Demodex Blepharitis
Psychosocial Impact of Demodex Blepharitis Open
Demodex blepharitis has a significant negative impact on daily activities and the mental and physical well-being of afflicted patients.
View article: Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1) Open
Purpose: The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis. Methods: In this prospective, randomized, controlled, doubl…
View article: Treatment of <i>Demodex</i> Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle
Treatment of <i>Demodex</i> Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle Open
Twice-daily 42-day treatment with novel lotilaner ophthalmic solution, 0.25% is safe and effective for the treatment of Demodex blepharitis compared to the vehicle control. (Registry number: ACTRN12620000320954, dated 09/03/2020).
View article: Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study
Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study Open
Purpose. Evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis. Patients and Methods. 15 patients with Demodex blepharitis, defined as >10 collarettes on the upper lid, lid ma…
View article: Collarette Elimination and <i>Demodex</i> Mite Eradication with Topical Lotilaner Ophthalmic Solution, 0.25%
Collarette Elimination and <i>Demodex</i> Mite Eradication with Topical Lotilaner Ophthalmic Solution, 0.25% Open
Purpose: To evaluate the efficacy of topical lotilaner ophthalmic solution, 0.25%, in patients with Demodex blepharitis. Methods: Eighteen adults with Demodex blepharitis, defined as >10 collarette…
View article: Safety and Efficacy of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: The EUROPA Study
Safety and Efficacy of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: The EUROPA Study Open
View article: Symptom improvement in dry eye subjects following intranasal tear neurostimulation: Results of two studies utilizing a controlled adverse environment
Symptom improvement in dry eye subjects following intranasal tear neurostimulation: Results of two studies utilizing a controlled adverse environment Open
Acute symptom relief is significant with the ITN and remains undiminished after daily use.
View article: Tear Total Lipid Concentration in Patients with Dry Eye Following Intranasal Neurostimulation
Tear Total Lipid Concentration in Patients with Dry Eye Following Intranasal Neurostimulation Open